Aton
ALTAO.PA
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.9M
Close$
$-0.01
199.2% downside
Current Fair Value
199.2% downsideOvervalued by 199.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.90 Million |
|---|---|
| Enterprise Value | $9.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.72 |
| Outstanding Shares | 383,149,844 |
Return
| Return on Equity | -52287.84% |
|---|---|
| Return on Assets | -333.16% |
| Return on Invested Capital | -57.63% |
Valuation & Multiples
| P/E Ratio | -13 |
|---|---|
| PEG | 1.79 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 24.78 |
| Enterprise Value to EBIT | -5.41 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.53 |
| Debt to Equity | 136.81 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aton
13 employees
CEO: Hadrien Lanvin Based in France, Aton operates as a bioscience enterprise, with its headquarters located in Strasbourg. Established in 1998, the company's extensive operations encompass pharmaceutical research and development, the provision of preclinic...